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Abstract
Background: Hepatitis C virus (HCV) genomes and proteins are present in human brain tissues although the impact of HIV/
HCV co-infection on neuropathogenesis remains unclear. Herein, we investigate HCV infectivity and effects on neuronal
survival and neuroinflammation in conjunction with HIV infection.
Methodology: Human microglia, astrocyte and neuron cultures were infected with cell culture-derived HCV or exposed to
HCV core protein with or without HIV-1 infection or HIV-1 Viral Protein R (Vpr) exposure. Host immune gene expression and
cell viability were measured. Patch-clamp studies of human neurons were performed in the presence or absence of HCV
core protein. Neurobehavioral performance and neuropathology were examined in HIV-1 Vpr-transgenic mice in which
stereotaxic intrastriatal implants of HCV core protein were performed.
Principal Findings: HCV-encoded RNA as well as HCV core and non-structural 3 (NS3) proteins were detectable in human
microglia and astrocytes infected with HCV. HCV core protein exposure induced expression of pro-inflammatory cytokines
including interleukin-1b, interleukin-6 and tumor necrosis factor-a in microglia (p,0.05) but not in astrocytes while
increased chemokine (e.g. CXCL10 and interleukin-8) expression was observed in both microglia and astrocytes (p,0.05).
HCV core protein modulated neuronal membrane currents and reduced both b-III-tubulin and lipidated LC3-II expression
(p,0.05). Neurons exposed to supernatants from HCV core-activated microglia exhibited reduced b-III-tubulin expression
(p,0.05). HCV core protein neurotoxicity and interleukin-6 induction were potentiated by HIV-1 Vpr protein (p,0.05). HIV-1
Vpr transgenic mice implanted with HCV core protein showed gliosis, reduced neuronal counts together with diminished
LC3 immunoreactivity. HCV core-implanted animals displayed neurobehavioral deficits at days 7 and 14 post-implantation
(p,0.05).
Conclusions: HCV core protein exposure caused neuronal injury through suppression of neuronal autophagy in addition to
neuroimmune activation. The additive neurotoxic effects of HCV- and HIV-encoded proteins highlight extrahepatic
mechanisms by which HCV infection worsens the disease course of HIV infection.
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Introduction
Hepatitis C virus (HCV) infects approximately 180 million
people worldwide [1] while 30% of individuals infected with
human immunodeficiency virus type 1 (HIV-1) are co-infected
with HCV due to similar routes of transmission [2]. Epidemio-
logical studies suggest that HCV co-infection is associated with
accelerated HIV disease progression, worsened clinical outcomes
and increased mortality [2,3]. HIV/HCV co-infected patients
have higher HCV levels and lower likelihood of spontaneous HCV
clearance, together with faster progression to liver cirrhosis [1,2].
HCV is a member of the Flaviviridae family, which consists of
several neurotropic viruses including St Louis encephalitis virus,
Dengue and West Nile virus [4,5]. HCV mono-infected and HIV/
HCV co-infected individuals display neuropsychological deficits
indicative of impaired cognition [5,6,7]. Magnetic resonance
spectroscopy studies report alterations in cerebral metabolites
among HCV-infected individuals correlated with neurocognitive
impairment, including suppression of the neuronal marker, N-
acetyl aspartate [8].
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from HIV/HCV co-infected patients, indicating that HCV is
neuroinvasive [9,10,11]. The negative strand of HCV RNA, a
viral replication intermediate, has been detected in the brain and
cerebrospinal fluid [10,12]. Several studies showed that HCV
RNA sequences isolated from the central nervous system (CNS)
were closely related to those found in peripheral blood mon-
onuclear cells (PBMC) but were phylogenetically different from
serum- or liver-derived sequences [10,11,12,13], leading to the
postulation that HCV enters the brain through the ‘Trojan horse’
mechanism similar to HIV-1 [4]. However, the mechanisms by
which HCV exerts neuropathogenic effects remain unknown and
the understanding of combined neuropathogenesis of HCV and
HIV-1 is limited.
HIV-1 exerts its direct neurotoxic effects through several
secreted proteins including gp120, Tat, Nef and Vpr [14]. HIV-
1 Viral Protein R (Vpr) triggers neuronal apoptosis and transgenic
mice expressing Vpr in brain monocytoid cells display neuronal
injury as well as neurobehavioral deficits [15]. Resident brain
macrophages or microglia infected with HIV-1 or exposed to
HIV-encoded proteins secrete proinflammatory cytokines e.g.
interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a) and
chemokines e.g. CXCL10 and CXCL12, which cause neuronal
death and pathogenic immune responses in the brain [14].
Suppression of neuronal autophagy by retroviral infections has
been highlighted as a putative mechanism leading to neuronal cell
death and neurodegeneration. The increased level of p62
transcript and the reduction of light chain 3 type II (LC3-II),
markers of autophagy inhibition, were detected in brain tissues of
patients with HIV-associated dementia [16,17].
Recently, HCV proteins including core, non-structural protein
3 (NS3) and NS5A were detected in macrophages/microglia and
astrocytes but not in neurons nor oligodendrocytes of patients with
HIV/HCV co-infection [9,18]. Nevertheless, the underlying
mechanisms by which HCV infects macrophages/microglia or
astrocytes remain unclear. The HCV JFH1 clone, derived from a
Japanese individual with fulminant hepatitis, replicates and
produces infectious virus in Huh 7.5 hepatocytes [19,20]. The
entry of HCV into cells involves several membrane receptors
including the scavenger receptor class B type I (SR-BI), the
tetraspanin CD81, and the tight-junction molecules, claudin-1 and
occludin [21]. Given these receptors are expressed by microglia
and astrocytes in human and mouse brains [22,23,24,25,26], these
cells are potentially permissive to infection by HCV.
The most abundantly expressed HCV protein, core, is released
and soluble in blood as a part of HCV morphogenesis [27] and
serum levels of HCV core protein ranges from pg/ml to ng/ml
[28]. HCV core protein is cytotoxic to hepatocytes through death-
receptor mediated apoptosis [29,30]; conversely, other studies
have demonstrated that HCV core protein has anti-apoptotic
effects in hepatocytes [29]. Recombinant HCV core protein fused
to b-galactosidase induces the production of inflammatory
cytokines, e.g. interleukin-6 (IL-6) and tumor necrosis factor-a
(TNF-a) in monocytes [31] as well as the chemokine CXCL8 in
monocytes [31] and lung fibroblasts [32]. Additionally, HCV core
protein has been implicated in suppressing differentiation,
proliferation and function of T cells, dendritic cells and
macrophages [33]. Herein, we investigated cell culture-derived
HCV (HCV
cc) infection of astrocytes and microglia as well as the
effects of HCV core protein on neurons, astrocytes and microglia
in the presence or absence of HIV-1 Vpr protein. The present
results demonstrated that HCV core protein caused immune
activation of glial cells and was neurotoxic in an additive manner
with the HIV-1 Vpr protein.
Materials and Methods
Reagents
Recombinant HCV core protein fused to b-galactosidase (Gal-
core, genotype 1b) and b-galactosidase (Gal) were obtained from
Virogen (Watertown, MA, USA). The full-length recombinant
HIV-1 Vpr protein was prepared as previously described [15].
Standard Protocol Approvals, informed consents and
ethic statements
The use of autopsied brain tissues and blood were approved
under the protocol number 2291 by the University of Alberta
Human Research Ethics Board (Biomedical) and written informed
consents were signed before or at the collection time. Human fetal
tissues were obtained from 15–19 week aborted fetuses with
written consent approved under the protocol 1420 by the
University of Alberta Human Research Ethics Board (Biomedical).
All animals were housed and monitored on a regular schedule
immediately following surgical implantation and behavioral tests
according to the Center For Animal Care and Control Guidelines.
This study was approved under the protocol number 452 by the
University of Alberta Animal Care & Use Committee for Health
Sciences.
Cell culture
Human fetal neurons were prepared and cultured in the
presence of cytosine arabinoside [34] while human fetal astrocytes
(HFAs) and human fetal microglia (HFmw) were grown in the
absence of cytosine arabinoside. Microglia were collected from
supernatants at 7 to 10 days after isolation while astrocytes were
split and used from the fifth to the tenth passage [35].
Human tissue samples
Human white matter, cortex, basal ganglion and spleen were
collected at autopsy and stored at 280uC. Non HIV-infected
controls were comprised of other neurological diseases including
Alzheimer’s disease, multiple sclerosis and stroke [16,36].
Hepatitis C viral preparation and infection
J6/JFH plasmid is a gift from Dr. Charles Rice (The Rockefeller
University, New York) [19]. The HCV-J6/JFH infectious virus
was prepared in Huh7.5 cells, as previously described [37]. HFAs
and HFmw were infected with supernatant containing HCV
cc
overnight before replacing with fresh media.
HIV-1 cultures
Human peripheral blood mononuclear cells (PBMCs) were
purified from healthy subjects’ blood with Histopaque (Sigma,
Oakville, Ontario, CA) [38]. Peripheral blood lymphocytes (PBLs)
were isolated from PBMCs and maintained in RPMI 1640
medium with 15% FBS with PHA-P stimulation for 3 days,
followed by hIL-2 stimulation. At day 3 post-isolation, PBLs were
infected with a neurotropic HIV-1 strain (HIV-1 SF162) and
supernatants were collected at day 7 and 10 post-infection.
Immunofluorescence
HFNs, HFAs and HFmw were plated on poly-L-ornithine
(Sigma) coated coverslips or Lab-Tex chambered coverglass
(Nunc, Rochester, NY). After 72 hr exposure to HCV
cc,H F mw
and HFAs were fixed, permeabilized and immuno-labelled with
mouse anti-HCV core (clone 11-B3, GeneTex, Irvine, CA) or
mouse anti-HCV NS3 (ab65407, Abcam, Cambridge, MA) and
rabbit anti-ionized calcium binding adaptor molecule 1 (Iba-1,
HCV Core Neuropathogenesis
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fibrillary acidic protein (GFAP, DAKO, Denmark) for HFAs.
After 48 hr of exposure to either Gal or Gal-core proteins, HFNs
were fixed, permeabilized and stained with antibodies to
microtubule-associated protein-2 (MAP-2, Sigma) and LC3
(Novus Biological, Littleton, CO). Paraffin-embedded sections
(6 mm) of mice brain tissue were deparaffinized and hydrated
followed by antigen retrieval with boiled 0.01 M citrate buffer,
pH 6.0, for 10 min. Brain sections were immunostained with anti-
GFAP, anti-Iba-1 or anti-LC3 antibodies. After primary antibody
incubation, cells and tissue sections were exposed to species-
specific secondary antibodies labeled with Alexa Flour 488
(Invitrogen, Eugene, OR) and/or Cy3 (Jackson ImmunoResearch,
West Grove, PA) [15]. Images were collected using an inverted
LSM510 Meta confocal microscope.
Real-time RT-PCR
HFmw and HFAs in 6-well plates were exposed to either Gal or
Gal-core proteins for 12 hr or as stated. RNA was extracted with
TRIzol (Invitrogen) and purified by RNeasy mini columns
(Qiagen, Mississauga, Ontario, Canada). First-strand complemen-
tary DNA (cDNA) was synthesized from 1 mg of total RNA mixed
with random hexamer primers (Roche) and Superscript II reverse
transcriptase (Invitrogen) according to the manufacturer’s recom-
mended protocols. Semiquantitative real-time PCR was per-
formed using Bio-Rad iQ SYBR green supermix (Bio-Rad,
Hercules, CA) on Bio-Rad iQ5. All PCR primers are shown in
Table S1. Data were normalized to GAPDH mRNA levels and
expressed as relative fold increases compared with controls 6
SEM. For the positive-strand or negative-strand assays, antisense
HCV-114R (59-GAGGCTGCACGACACTCATACT-39) and
sense primer HCV-20F (59-CGACACTCCACCATGAATCA-
CT-39) were used for cDNA synthesis [39]. PlatinumH Quantita-
tive PCR SuperMix-UDG and TaqMan probe HCV-P43
(59FAM-CCCTGTGAGGAACTACTGTCTTCAC-GCAGA-T-
AMRA39) were used for strand-specific real-time PCR.
Enzyme-linked immunosorbent assay (ELISA)
Supernatants from Gal- or Gal-core treated HFAs were
collected at 6, 12, 24 and 48 hr after treatments and amount of
CXCL8 was measured using a human CXCL8 ELISA Ready-
SET-Go (eBioscience, San Diego, CA).
Electrophysiological studies
Whole-cell patch-clamp recordings from HFNs were performed
under voltage-clamp conditions [15].
Western blotting
6 hr after Gal or Gal-core exposure, HFNs were lysed in lysis
buffer [20 mM Tris, 1% NP-40, 50 mM NaCl, Protease Inhibitor
cocktail set III (1:1000, Calbiochem, La Jolla, CA)]. Crude protein
lysates were separated by 16% SDS-PAGE and the membrane
were blotted for LC3 and b-actin (Santa Cruz Biotechnology,
Santa Cruz, CA). Immunoreactive bands were visualized using
HRP-conjugated secondary antibodies and quantitated using
Quantity One
TM (Bio-Rad) imaging software.
In vitro cytotoxicity assay
HFNs or HFAs were plated at 5610
4 and 2610
4 cells in 96-well
flat bottom plates and exposed to either Gal or Gal-core protein
with and without Vpr. After 48 h of exposure, cells were fixed,
permeabilized and stained with anti-b-tubulin antibodies (Sigma).
Neuronal injury was quantified by b-III-tubulin immunoreactivity
using OdysseyH Imager (LI-COR, Lincoln, NE). Diminished b-
III-tubulin immunoreactivity in neurons is an indicative of
reduced cellular viability including neurite retraction and impaired
survival [15].
Neurobehavioral studies
Vpr transgenic mice express Vpr under the control of the c-fms
(M-CSF receptor) promoter, driving transgene expression chiefly in
monocytoid cells [40]. In vivo neurological injury was assessed using
the Ungerstedt model [41,42] in Vpr transgenic mice. Female
animals (4 weeks, n=6) were placed in a stereotaxic frame under
Ketamine/Xylazine anesthesia. The coordinates of implantation
were 3.5 mm posterior, 2.5 mm lateral and 3 mm deep relative to
the bregma. 2 ml of Gal or Gal-core was stereotactically implanted
into the right striatum of mice. Ipsiversive rotation number was
countedover 10 min after intraperitonealinjection of amphetamine
(1 mg/kg) on days 4, 7 and 14 following intrastriatal injection.
Neuronal count
After deparaffinization and hydration, mice brain sections were
stained with 0.1% cresyl violet solution. Neurons were counted at
4006 magnification in 4 separate non-overlapping fields. The
number of neurons in the ipsilateral (right) side was normalized to
those in the non-implanted contralateral (left) side [41].
Statistical analysis
Data were tested by one-way analysis of variance (ANOVA)
with Bonferroni post hoc tests or a two-tailed unpaired Student’s t
test. The level of significance was defined as p,0.05.
Results
HCV RNA quantification in infected brain and protein
detection in infected microglia and astrocytes
HCV-encoded proteins as well as positive and negative RNA
strands have been reported in different brain regions and identified
specifically in microglia/macrophages and astrocytes [9,10,18]. To
verify HCV infection of the brain occured, autopsied brain tissues
were investigated in HIV/AIDS persons without HCV infection
(n=3) and an individual with HIV/AIDS and HCV infection at
death. The latter individual was a 46-year old female patient with
HIV-associated dementia (HIV Dementia Scale score =6; cranial
MRI: cerebral atrophy with increased diffuse white matter signal on
T2-weighted images), CD4
+ T cell level =105 cells/mla n d
detectable HIV and HCV viremia. HCV RNA positive- and
negative-strand copy numbers were determined in brain samples
from all patients by a strand-specific reverse transcriptase with
subsequent PCR amplification and interpreted from a standard
curve. Positive-strand HCV RNA was detectable in white matter,
cortex and basal ganglia from the HIV/HCV co-infected patient at
10
2 viral copies/mg RNA, which were 10-fold lower than viral copy
numbers in the matched spleen (Figure 1A). In contrast, negative-
strand RNA, an indication of viral replication, was found only in
white matter and basal ganglia but not in cortex (Figure 1B), as
previously reported [10]. HCV-encoded RNA was not detected in
control groups and HIV/AIDS persons without HCV viremia. To
determine if human glia were permissive to HCV infection, primary
cultures of HFAs and HFmw were exposed to supernatants from J6/
JFH1 transfected Huh 7.5 cells containing infectious virus
(10
3 FFU/ml, multiplicity of infection or m.o.i. =1). At day 3
post-infection, HCV positive-strand RNA were detected in all
HCV
cc-infected astrocytes at 10
2 to 10
3 viral copies/mg RNA while
negative strands of HCV RNA were evident in only 75% of infected
astrocyte cultures (Figure 1C). Similarly, HCV positive- and
HCV Core Neuropathogenesis
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3 viral copies/mg RNA in
HCV
cc-infected microglia (Figure 1D). Both HCV core and NS3
proteins were detectable in cytoplasm of GFAP (astrocytes) and Iba-
1 (microglia) immunopositive cells compared to mock infection
(Figure 1E and Figure S1). These studies highlighted the capacity of
HCV to infect the select neural cells, particularly glial cells.
HCV core protein induces differential inflammatory
responses in microglia and astrocytes
Exposure of HCV core protein to human blood monocytes
activated the expression and release of pro-inflammatory cytokines
[31]. To investigate the neuroinflammatory effects of HCV core on
microglia/macrophages and astrocytes, HFmw and HFAs were
exposed to Gal-core or Gal (10 nM) for 12 hours and transcript
levels of cytokines and chemokines were measured. HCV core
induced expression of the pro-inflammatory cytokine IL-1b by 80
fold in HFmw (Figure 2A, p,0.05) while there was only a trend of
increased IL-1b expression in HFA (Figure 2B). Likewise, the
expression of IL-6 and TNF-a transcripts was significantly higher in
HCV core-exposed HFmw (Figure 2C and 2E, p,0.05) but not in
HCV core-exposed HFAs (Figure 2D and 2F). Of interest, HCV
core protein exposure did not activate the expression of interferon-
alpha (IFNa) transcripts in both glial cell types (data not shown).
In addition to cytokine induction, HCV core protein has been
reported to promote expression of chemokines, e.g. CXCL10,
CXCL8 and CCL5, in monocytes and other cell types including
hepatocytes and fibroblasts [31,32,43,44]. After HCV core
exposure (12 hr), HFmw expressed elevated levels of CXCL10 and
CXCL8 transcripts (Figure 3A and 3C, p,0.05).Similarly, transcript
levels of CXCL10 and CXCL8 in HFAs were increased at 6 and
12 hr after HCV core protein application (Figure 3B and 3D,
p,0.05). There was no difference in transcript levels for CCL5 and
CXCL12 in HFAs (data not shown). The supernatant levels of
CXCL8 protein derived from exposed HFAs increased with time
and reached a plateau by 24 hr post-exposure (Figure 3E, p,0.05).
Direct or indirect exposure of HCV core protein results in
neuronal injury
Given HCV core protein has been detected in white and gray
matters [9], its cytotoxic effects on HFAs and HFNs were
investigated. HCV core protein exposure was not toxic to
astrocytes (Figure 4A) while the highest concentration of HCV
core protein (100 nM) was cytotoxic to neurons, indicated by the
loss of b-III-tubulin expression compared to controls (Figure 4B,
p,0.05). HCV core protein (100 nM) also reduced neuronal
survival compared to controls as indicated by DAPI staining (data
not shown). To determine if HCV core protein exerted its
neurotoxic effects indirectly through induction of neurotoxic
factors secreted by microglia or astrocytes, supernatants from
HFAs or HFmw exposed to Gal-core (10 nM) were collected at 24
and 48 hour post-exposure and then applied to HFNs. Superna-
tants from HCV core-exposed HFAs showed no neurotoxicity
(Figure 4C) while supernatants from HCV core-exposed HFmw
caused neuronal injury (Figure 4D, p,0.05). These results
suggested that HCV core protein was toxic to neurons through
both direct and indirect mechanisms.
HCV core protein alters neuronal membrane response
and suppresses neuronal autophagy
To define the mechanisms that underlie the direct neurotoxic
effects of HCV core protein, the actions of HCV core protein were
examined on neuronal membrane activity. Under voltage-clamp
conditions in purified HFNs, HCV Gal-core (100 nM) reduced
whole-cell outward currents in the voltage range from 230 to
+30 mV relative to Gal exposure. This effect was reversible after the
wash-out period (Figure 5A), indicating that HCV core protein was
directly active at the neuronal membrane. Recently, neuronal
autophagy suppression has been recognized as a key mechanism in
several neurodegenerative disorders [45] and participates in the
neurovirulence of several viruses [16,46]. The role of autophagy in
HCV core-mediated neurotoxicity was investigated by measuring the
levels of light chain 3 (LC3), a marker of autophagosome formation.
HFNs exposed to Gal protein displayed healthy MAP-2 immuno-
positive cells with long and complex neurites (Figure 5Bi); in contrast,
HCV core-exposed neurons exhibited fewer MAP-2 immunopositive
cells with shorter processes and atrophied soma (Figure 5Bii).
Additionally, LC3 was highly expressed in Gal-exposed neurons
(Figure 5Bi, inset). Western blot analysis of neuronal lysates showed a
reduction of LC3-II expression in HCV core-exposed HFNs
compared with control HFNs (Figure 5C, p,0.05), indicating that
HCV core protein inhibited LC3-I to LC3-II conversion. These data
i m p l i e dt h a tH C Vc o r ep r o t e i nc o u l da c ta tt h en e u r o n a lm e m b r a n e ,
contributing to neuronal death by modulating neuronal autophagy.
HIV-1 infection and Vpr protein potentiate the
neuroimmune activation and neurotoxic effects of HCV
core protein
Brain mononuclear cells in HIV-infected persons are known to
produce several proinflammatory cytokines such as IL-1b and
TNF-a [14]. To determine if HCV core protein exacerbated
cytokine and chemokine expression in HIV-1-infected microglia,
HCV core protein was applied to HFmw infected by HIV-1 SF162,
a neurotropic HIV-1 strain. HIV-1 infection in microglia was
confirmed by detecting HIV-1 pol expression (data not shown). As
expected, HIV-1 infection induced expression of IL-1b, IL-6,
TNF-a and CXCL8 (Figure 6A). However, HCV core exposure
(12 hr) increased IL-6, TNF-a, CXCL10 and CXCL8 expression
from 2 to 29 fold compared to Gal-exposed cells (Figure 6A,
p,0.05). These studies were extended by showing that concurrent
exposure of HIV-1 Vpr with HCV core proteins caused higher IL-
6 expression than HCV core-treated HFmw (Figure 6B) while there
was no additive effect on the induction of other cytokines and
chemokines (data not shown). In addition, soluble HIV-1 Vpr
protein at a subneurotoxic concentration (50 nM) together with
HCV core protein (10 and 100 nM) caused significantly increased
HFN injury (Figure 6C) indicated by reduced b-III-tubulin
Figure 1. HCV RNA and proteins were detectable in different brain regions and infected glia cells. (A and B) Quantification of HCV-
encoded positive- (A) and negative-strand (B) RNA of three brain regions from an HIV/HCV co-infected patient displayed different abundance of RNA
in white matter (WM), cortex (CTX) and basal ganglion (BG) compared to spleen (SP). Negative-strand RNA of HCV was only detectable in basal
ganglion, spleen and one sample from white matter. HCV RNA was not detected in white matter tissues from control (CTL) and HIV-1 mono-infected
(HIV) individuals. (C and D) Primary cultures of human fetal astrocytes (HFA) and human fetal microglia (HFmw) were exposed to supernatant
containing HCV
cc. The levels of HCV positive- and negative-strands were measured by real time RT-PCR with strand specific primers at day 3 post-
infection (HFA, n=12; HFmw, n=5). (E) Immunofluorescence of HCV core and NS3 proteins in J6/JFH1-infected primary HFA and HFmw showed co-
labeling of HCV-encoded proteins (green) with GFAP-immunoreactive astrocytes (red) or Iba-1-immunoreactive microglia (red) in HCV-infected cells
at day 3 post-infection but not in mock-infected cells. Insets showed core and NS3-immunopositive HFA and HFmw. (original magnification 630x)
doi:10.1371/journal.pone.0012856.g001
HCV Core Neuropathogenesis
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Vpr or HCV core proteins at the same concentrations (p,0.05).
These results indicated that concurrent exposure of HIV-1 and
HCV encoded proteins potentiated the neuroimmune activation
and neurotoxicity effects of HCV core protein.
HCV core protein causes neuropathological and
neurobehavioral deficits in Vpr-transgenic mice
As the present in vitro studies exhibited additive neurotoxic effects
of HCV core and HIV-1 Vpr proteins, Gal-core or Gal proteins
werestereotacticallyimplantedinto therightstriatumof HIV-1Vpr-
transgenic mice. These transgenic animals were previously shown to
exhibit features indicative of neurodegeneration [15,47]. Morpho-
logical analysis at day 14 post-implantation disclosed increased
immunoreactivity of GFAP, an astrocyte marker, and Iba-1, a
microglia/macrophage marker, in the right striatum of Vpr-
transgenic mice receiving HCV core protein implantation
(Figure 7Aiv and v). Additionally, HCV core-implanted animals
displayed lower LC3 immunoreactivity (Figure 7Avi) and reduced
numbers of cresyl violet-positive cells in the right striatum
(Figure 7Bii). Mean ratios of ipsilateral to contralateral neuronal
countsconfirmedneuronallossintheimplantedstriatum(Figure7B).
In conjunction with these latter neuropathological features, Vpr
Figure 2. Recombinant HCV core protein activated microglia. Primary human fetal microglia (HFmw) and astrocytes (HFA) were exposed to
culture medium (mock, 2), Gal (10 nM) or Gal-core (10 nM) for 12 hr. Gal-core-exposed HFmw displayed elevated mRNA expression for IL-1b (A), IL-6
(C) and TNF-a (E) while cytokine expression in Gal-exposed HFmw was similar to mock-exposed cells. In contrast, Gal-core-exposed HFAs showed
similar transcript levels for IL-1b (B), IL-6 (D) and TNF-a (F) compared with mock-treated cells (n=4). mRNA expression was reported as relative fold
change (RFC) compared to GAPDH expression. Data represent mean6SEM for five or more independent experiments (one-way ANOVA with
Bonferroni post hoc tests, * p,0.05 compared to mock-treated cells).
doi:10.1371/journal.pone.0012856.g002
HCV Core Neuropathogenesis
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ipsiversive rotation frequency at days 7 and 14 post-implantation
(Figure 7C, p,0.05). Taken together, the in vivo neurotoxicity of
HCV core protein was likely a consequence of autophagy
suppression in neurons coupled with activation of proximate
astrocytes and microglia leading to neuronal injury and loss.
Discussion
During the last decade, there is mounting evidence to suggest
HCV is neuroinvasive and HIV/HCV co-infected patients display
higher rates of neuropsychological deficits. To delineate the
underlying pathogenic mechanisms of HCV infection of the brain,
we report for the first time that primary human astrocytes and
microglia were permissive to HCV infection with cell culture-
derived HCV particles. Moreover, this report demonstrates for the
first time that HCV core protein activates human glia and
contributes to neurotoxicity. Direct exposure of HCV core protein
to primary human neurons suppressed the neuronal autophagy,
leading to neurite retraction. The change in neuronal membrane
potential after exposure to HCV core protein indicated that core
was biologically active at the cell membrane and was able to
Figure 3. HCV core protein induced chemokine expression in microglia and astrocytes. Primary human fetal microglia (HFmw) (A, C) and
astrocytes (HFA) (B,D) exposed to 10 nM Gal-core displayed elevated mRNA expression for CXCL10 (A, B) and CXCL8 (C, D). The increased CXCL10 and
CXCL8 expression in Gal-core-treated HFA was highest at 6 hr post-exposure and extinguished at 24 hr post-exposure. (E) Elevated levels of CXCL8
protein were detected in supernatants from Gal-core-treated HFAs after 12 hr exposure by ELISAs. Data represent mean6SEM for three or more
independent experiments (one-way ANOVA with Bonferroni post hoc tests, * p,0.05 compared to mock-treated cells).
doi:10.1371/journal.pone.0012856.g003
HCV Core Neuropathogenesis
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neurotoxicity, proinflammatory cytokines and other neurotoxins
released from HCV core-activated microglia into supernatants
were toxic to neurons. The in vitro and in vivo aberrant immune
activation and neurotoxicity mediated by HCV core protein were
amplified in the presence of HIV-1 Vpr protein. These findings
support the concept that the presence of HCV-encoded proteins
cause neuronal damage and perhaps neurocognitive impairment
in individuals co-infected with HIV and HCV.
Although HCV tropism is principally recognized in human liver
cells, extrahepatic replication has been reported in PBMC [48],
myocardium [49,50] and brain cells [10,18] by detecting HCV
negative-strand RNA. Herein, detection of positive- and negative-
strand RNA in different brain regions was performed in a patient
with HIV and HCV co-infection and was consistent with previous
reports [10,18]. HCV
cc infects and replicates in Huh 7.5
hepatocytes. However, productive infection was not detected in
other hepatic cell lines (e.g. HepG2) [20], non-hepatic cell lines
(e.g. HeLa, 293T and U-937) [20] and PBMC (e.g. B and T
lymphocytes, monocytes and dendritic cells) [51], likely due to the
lack of some entry receptors e.g. claudin-1 and their partner
proteins [51] or host factors required for HCV infection e.g. liver
specific microRNA miR-122 [52,53,54]. Herein, expression of
HCV proteins, core and NS3, were immunodetected in the
cytoplasm of primary human astrocytes and microglia infected
with HCV
cc. Although the levels of infectivity in primary
astrocytes and microglia were low (less than 1%), HCV positive-
and negative-strand RNA were measurable in infected astrocytes,
suggesting that HCV is capable of replication in astrocytes. Both
microglia and astrocytes were previously identified as HCV-
infected cells in autopsied brains [9,18] and were shown to express
SR-BI, CD81, claudin-1 and occludin [22,23,24,25,26]. Although
the expression levels of claudin-1 and occludin were 15 to 50 fold
lower in primary human astrocytes and microglia compared with
Huh 7.5 cells (Figure S2A), claudin-1 expression in glial cells was
approximately 10 fold higher than in PBMC or 293T cells [51].
The higher expression of HCV entry receptors in primary
astrocytes compared to microglia was also consistent with less
Figure 4. Neurotoxicity mediated by HCV core protein. Cell injury was determined by measuring b-III tubulin immunoreactivity at 48 hr post-
exposure. (A) Gal or Gal-core exposure did not affect the viability of primary human fetal astrocytes (HFA). (B) Gal-core (100 nM) exposed to HFNs
suppressed neuronal viability in terms of reduced b-tubulin immunoreactivity. (C) Supernatants from Gal- or Gal-core-treated astrocytes (HFA S/N)
was not toxic to primary human fetal neurons (HFN, n=3). (D) Supernatants from Gal-core-exposed microglia (HFmw S/N) collected at 24 and 48 hr
post-exposure also caused a reduction in b-tubulin immunoreactivity of HFNs. Data represent mean6SEM for three or more independent
experiments (one-way ANOVA with Bonferroni post hoc tests, * p,0.05 compared to mock-treated cells).
doi:10.1371/journal.pone.0012856.g004
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cc
infection. HCV replication in infected or transfected hepatocytes
was reported in the membranous web structure closely associated
with rough endoplasmic reticulum [55]. In the present studies,
localization of HCV proteins in astrocytes was similarly associated
with structures resembling endoplasmic reticulum. Further studies
to determine if HCV-infected microglia or astrocytes release
infectious viruses will be of interest.
HCV
cc used herein belongs to the HCV genotype 2a [19] while
most HCV strains in North America are genotypes 1a or 1b,
which are associated with higher HCV RNA levels, poor responses
to IFN-a treatment and lower mean CD4 count in HIV/HCV co-
infected individuals [2]. The strain difference and other co-
morbidities such as intravenous drug use might influence the
infection and production of HCV in human brain, as demon-
strated for HIV infection [56].
Figure 5. HCV core protein modulated neuronal membrane conductance. (A) Whole-cell currents recorded from human fetal neurons
(HFNs) were reduced after exposure to Gal-core (100 nM, n=4) but not Gal (100 nM, n=6). (B) After Gal-core (100 nM) exposure, MAP-2-
immunopositive HFNs (green) showed neurite retraction, fewer neurite processes, soma atrophy and loss of neurons (ii) compared to Gal (100 nM)
exposure (i). The autophagy-related light chain 3 (LC3) molecule was widely expressed in unexposed neurons (red, i, inset) (original magnification
636). (C) LC3 immunoreactivity of HFN lysates showed two isoforms of LC3: cytosolic LC3-I (top band) and its phosphatidylethanolamine-conjugated
LC3-II (bottom band). 6 hr after exposure to 100 nM Gal-core, the band density ratio of LC3-II to LC3-I was reduced by 37.5% compared to mock-
exposed cells. Data represent mean6SEM (n=4, one-way ANOVA with Bonferroni post hoc tests, * p,0.05).
doi:10.1371/journal.pone.0012856.g005
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with changes indicative of neuronal damage by magnetic
resonance spectroscopy [8]. Herein, we demonstrated that the
direct exposure of HCV core protein or exposure to supernatants
from HCV core-exposed microglia were toxic to primary human
neurons together with neurobehavioral deficits and neuronal loss
in HCV core-implanted animals. Although the toxic concentration
of HCV core for primary human neurons in our in vitro
experiments was higher than the reported serum levels in HCV-
infected patients, it was consistent with previous studies [31,32,57].
It is plausible that HCV core concentrations at the surface of
infected and proximate (target) cells are higher than in serum;
moreover, chronic and repeated HCV exposures might yield
augmented neurotoxic effects. Remarkably, the concentration of
HCV core required to activate microglia and astrocytes was one
log less than the concentration needed for direct neurotoxicity.
HIV-1 Vpr is highly neurotoxic without substantial proinflam-
matory properties [58] and its expression in brain monocytic cells
contributes to synaptic injury and neurobehavioral abnormalities
in transgenic mice [15]. At subtoxic concentrations, simultaneous
exposure of HCV core and HIV-1 Vpr proteins to neurons
exerted additive effects, resulting in increased IL-6 expression in
glial cells and neuronal injury. Likewise, implantation of HCV
core into the striatum of HIV-1 Vpr transgenic mice resulted in
marked glial activation coupled with neuronal loss. It is likely that
Vpr and HCV core act through different mechanisms to yield
cumulative neurotoxic effects as Vpr’s putative receptor is the
nuclear glucocorticoid receptor [59] while HCV core’s receptor
might be a cell membrane protein [31,32,57,60]. Additionally, it is
conceivable that HCV core protein might also potentiate the
neurotoxic or neuroinflammatory effects of other HIV-1 proteins
e.g. Tat, Nef or gp120. This possibility might highlight the
importance of interactions between HCV and HIV and warrants
further investigation.
Our data showed that core protein from HCV genotype 1b
triggered in vitro and in vivo activation of microglia and astrocytes,
Figure 6. HCV core protein increased microglia activation and neurotoxicity induced by HIV-1 infection and Vpr protein. (A) Primary
human fetal microglia (HFmw) were infected with HIV-1 SF162. At day 2 post-infection, HIV-1-infected HFmw were exposed to culture medium (HIV-1),
Gal (10 nM, HIV-1+Gal) or Gal-core (10 nM, HIV-1+Core) for 12 hr. HIV-1 infection caused increased mRNA expression of IL-1b, IL-6, TNF-a and CXCL8.
Exposure to Gal-core potentiated transcript expression of IL-6, TNF-a, CXCL10 and CXCL8 expression compared to HIV-1-infected microglia exposed to
mock or Gal. (B) HFmw exposed to HIV-1 Vpr (50 nM) and Gal-core (10 nM) proteins displayed elevated IL-6 transcript levels compared to Vpr- or Gal-
core-treated cells. (C) Concomitant exposure of primary human neurons (HFN) to HIV-1 Vpr and Gal-core also resulted in reduced b-tubulin
immunoreactivity compared to mock- or Vpr-exposed cells in a concentration dependent manner. Data represent mean6SEM for three or more
independent experiments (one-way ANOVA with Bonferroni post hoc tests, * p,0.05 and ** p,0.01 compared to mock-treated cells).
doi:10.1371/journal.pone.0012856.g006
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PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12856Figure 7. Implanted HCV core protein caused glial activation, neuronal loss and neurobehavioral deficits in Vpr-transgenic mice. (A)
GFAP and Iba-1 immunoreactivities were minimally detected in ipsilateral brain hemispheres of animals implanted with Gal (i, ii) while higher
numbers of GFAP and Iba-1 immunopositive cells were evident in Gal-core-implanted animals (iv, v). LC3 immunoreactivity was lower in Gal-core-
implanted animals (vi) compared to Gal-implanted animals (iii) (original magnification 636). (B) Nissl staining of ipsilateral basal ganglia displayed
lower numbers of neurons in Vpr transgenic mice implanted with Gal-core (ii) compared with Gal (i) (original magnification 4006). Neurons were
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study that revealed an increased level of myo-inositol, a hallmark of
gliosis, in frontal white matter of HCV-infected individuals [61].
Increased serum TNF-a and IL-1b levels in HCV-infected
individuals were correlated with severity of neuropsychiatric
dysfunction [62]. In vitro HCV infection in primary human
macrophages resulted in increased TNF-a and CXCL8 [63].
Increased expression of CXCL10 and CXCL8 in astrocytes was
also reported in brains of individuals with HIV encephalitis [64]. A
recent study demonstrated that HIV-infected macrophages
induced CXCL8 production from astrocytes through IL-1b and
TNF-a [65]. The chemoattractant CXCL10 plays an important
role in leukocyte infiltration into various tissues including CNS
[66]. CXCL8 recruits not only neutrophils but also monocytes and
lymphocytes [67]. It is plausible that the increased expression of
CXCL10 and CXCL8 by HCV core-exposed microglia and
astrocytes might enhance recruitment of T helper cells and
monocytes in the brain, leading to deleterious effects. Of interest,
we also observed that HCV core exposure to microglia induced
the transcript levels of indoleamine 2,3-dioxygenase (IDO) (data
not shown), which has been linked to neuronal injury [68,69].
Additionally, we also demonstrated that supernatants from HCV
core-treated microglia were neurotoxic. In these experiments, the
concentration of HCV core protein was subtoxic to neurons but
was sufficient to induce the expression of neurotoxic factors. It is
also possible that there was carry-over of HCV core protein in
supernatants which might play a role in the overall neurotoxicity.
However, these results indicate that exposure of HCV core protein
to glial cells could lead to deleterious effects on neurons.
Several studies have reported that recombinant HCV core
activated cell surface receptors e.g. Toll-like receptor 2 (TLR2) on
monocytes [31] and dendritic cells [70] or the putative HCV core
receptor, gC1qR, on T lymphocytes [57,60] and lung fibroblasts
[32]. Microglia/macrophages are known to express both receptors
[71,72] while astrocytes express gC1qR but not TLR2 [72,73] and
there was a 30% increase in the gC1qR transcript level in HIV-
infected brains (Figure S2B). Inhibition of either TLR2 or gC1qR
by blocking antibodies or RNA silencing will be of interest.
Nonetheless, HCV core might also be endocytosed by the
microglia or astrocytes, and subsequently act through intracellular
or nuclear receptors.
In summary, we reported primary human microglia and
astrocytes were permissive to HCV infection and HCV-encoded
protein, core, was neurotoxic but also activated pro-inflammatory
responses in human microglia and astrocytes. The augmented glial
activation and neurotoxicity mediated by HCV core protein in the
presence of HIV-1 Vpr protein or HIV-1 infection highlighted the
additive effects of HCV- and HIV-encoded proteins in the
pathogenesis of neurologic disease. Future studies are required to
delineate the precise mechanisms by which HIV and HCV
proteins interact and amplify neuropathogenesis, thereby permit-
ting the development of potential management and therapeutic
strategies.
Supporting Information
Table S1 Real-time RT PCR primer sequences for detecting
human genes.
Found at: doi:10.1371/journal.pone.0012856.s001 (0.06 MB
DOC)
Figure S1 Primary human astrocytes and microglia were
permissive to infection by HCVcc. At day 3 post-infection, HCV
core protein immunoreactivity (green) was colocalized with GFAP
or Iba-1 (red) in HCVcc-infected primary human fetal astrocytes
(HFA) and microglia (HFmW) but not in mock-infected cells.
(original magnification 630x)
Found at: doi:10.1371/journal.pone.0012856.s002 (4.39 MB TIF)
Figure S2 Expression of HCV entry receptors in glial cells and
brains. (A) Transcript expression of HCV entry receptors were
determined by real time RT-PCR. Primary human microglia and
astrocytes expressed all known HCV entry receptors, albeit at the
lower levels than Huh 7.5 hepatoma cell line. (B) Similar levels of
HCV entry receptors were found in white matter tissues from
control and individuals with HIV encephalitis (HIV) while the
expression of the gC1qR transcript was elevated in HIV compared
to control (n=5, * p,0.05). Data represent mean 6SEM for three
or more independent experiments.
Found at: doi:10.1371/journal.pone.0012856.s003 (0.81 MB TIF)
Acknowledgments
We are grateful to Dr. Charles Rice from The Rockefeller University, New
York for a J6/JFH plasmid. We thank Kristofor Ellestad and Maureen
MacKenzie for technical support and Krista Nelles for assistance with
manuscript preparation.
Author Contributions
Conceived and designed the experiments: PV CR BA EAC JJ CP.
Performed the experiments: PV FM LTL HN JJ. Analyzed the data: PV
FM. Contributed reagents/materials/analysis tools: LTL CR EAC. Wrote
the paper: PV CP.
References
1. Kim AY, Chung RT (2009) Coinfection with HIV-1 and HCV–a one-two
punch. Gastroenterology 137: 795–814.
2. Jones R, Dunning J, Nelson M (2005) HIV and hepatitis C co-infection. Int J Clin
Pract 59: 1082–1087.
3. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, et al. (2000) Clinical
progression, survival, and immune recovery during antiretroviral therapy in
patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort
Study. Lancet 356: 1800–1805.
4. Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, et al. (2005)
Emerging evidence of hepatitis C virus neuroinvasion. Aids 19(Suppl 3):
S140–144.
5. Clifford DB, Yang Y, Evans S (2005) Neurologic consequences of hepatitis C and
human immunodeficiency virus coinfection. J Neurovirol 11(Suppl 3): 67–71.
6. Hilsabeck RC, Castellon SA, Hinkin CH (2005) Neuropsychological aspects of
coinfection with HIV and hepatitis C virus. Clin Infect Dis 41(Suppl 1): S38–
44.
7. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P (2004) Neuropsychiatric
impact of hepatitis C on advanced HIV. Neurology 62: 957–962.
8. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, et al. (2005) A review of
cognitive impairment and cerebral metabolite abnormalities in patients with
hepatitis C infection. Aids 19(Suppl 3): S53–63.
9. Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, et al. (2007)
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected
with HIV. J Infect Dis 196: 361–370.
10. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, et al. (2002) Search
for hepatitis C virus negative-strand RNA sequences and analysis of viral
counted in four different fields of four sections from ipsilateral and contralateral hemispheres. Gal-core-implanted Vpr transgenic mice displayed a
lower ratio of ipsilateral to contralateral neuronal counts (n=3, two-tailed unpaired Student’s t test, * p,0.05). (C) In vivo neurological damage in Gal-
core-implanted Vpr transgenic mice was indicated by higher frequencies of ipsiversive rotations at days 7 and 14 post-implantation (n=6, repeated
measured ANOVA with Bonferroni post hoc tests, * p,0.05 compared to Gal-implanted animals). Data are presented as the mean6SEM.
doi:10.1371/journal.pone.0012856.g007
HCV Core Neuropathogenesis
PLoS ONE | www.plosone.org 12 September 2010 | Volume 5 | Issue 9 | e12856sequences in the central nervous system: evidence of replication. J Virol 76:
600–608.
1 1 .M u r r a yJ ,F i s h m a nS L ,R y a nE ,E n gF J ,W a l e w s k iJ L ,e ta l .( 2 0 0 8 )
Clinicopathologic correlates of hepatitis C virus in brain: a pilot study.
J Neurovirol 14: 17–27.
12. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, et al. (2002)
Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid.
J Virol 76: 10064–10068.
13. Fishman SL, Murray JM, Eng FJ, Walewski JL, Morgello S, et al. (2008)
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain.
J Infect Dis 197: 597–607.
14. Jones G, Power C (2006) Regulation of neural cell survival by HIV-1 infection.
Neurobiol Dis 21: 1–17.
15. Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, et al. (2007) HIV-1 Vpr
causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 27:
3703–3711.
16. Zhu Y, Vergote D, Pardo C, Noorbakhsh F, McArthur JC, et al. (2009) CXCR3
activation by lentivirus infection suppresses neuronal autophagy: neuroprotective
effects of antiretroviral therapy. Faseb J 23: 2928–2941.
17. Alirezaei M, Kiosses WB, Flynn CT, Brady NR, Fox HS (2008) Disruption of
neuronal autophagy by infected microglia results in neurodegeneration. PLoS
One 3: e2906.
18. Wilkinson J, Radkowski M, Laskus T (2009) Hepatitis C virus neuroinvasion:
identification of infected cells. J Virol 83: 1312–1319.
19. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005)
Complete replication of hepatitis C virus in cell culture. Science 309: 623–626.
20. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust
hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294–9299.
21. Burlone ME, Budkowska A (2009) Hepatitis C virus cell entry: role of
lipoproteins and cellular receptors. J Gen Virol 90: 1055–1070.
22. Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC (2002)
Scavenger receptors in neurobiology and neuropathology: their role on
microglia and other cells of the nervous system. Glia 40: 195–205.
23. Husemann J, Silverstein SC (2001) Expression of scavenger receptor class B, type
I, by astrocytes and vascular smooth muscle cells in normal adult mouse and
human brain and in Alzheimer’s disease brain. Am J Pathol 158: 825–832.
24. Dijkstra S, Geisert EJ, Gispen WH, Bar PR, Joosten EA (2000) Up-regulation of
CD81 (target of the antiproliferative antibody; TAPA) by reactive microglia and
astrocytes after spinal cord injury in the rat. J Comp Neurol 428: 266–277.
25. Duffy HS, John GR, Lee SC, Brosnan CF, Spray DC (2000) Reciprocal
regulation of the junctional proteins claudin-1 and connexin43 by interleukin-
1beta in primary human fetal astrocytes. J Neurosci 20: RC114.
26. Romanitan MO, Popescu BO, Winblad B, Bajenaru OA, Bogdanovic N (2007)
Occludin is overexpressed in Alzheimer’s disease and vascular dementia. J Cell
Mol Med 11: 569–579.
27. Maillard P, Krawczynski K, Nitkiewicz J, Bronnert C, Sidorkiewicz M, et al.
(2001) Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected
patients. J Virol 75: 8240–8250.
28. Soffredini R, Rumi MG, Parravicini ML, Ronchi G, Del Ninno E, et al. (2004)
Serum levels of hepatitis C virus core antigen as a marker of infection and
response to therapy. Am J Gastroenterol 99: 1738–1743.
29. Fischer R, Baumert T, Blum HE (2007) Hepatitis C virus infection and
apoptosis. World J Gastroenterol 13: 4865–4872.
30. Giannini C, Brechot C (2003) Hepatitis C virus biology. Cell Death Differ
10(Suppl 1): S27–38.
31. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, et al. (2004)
Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-
mediated pathways and inflammatory activation. Gastroenterology 127:
1513–1524.
32. Moorman JP, Fitzgerald SM, Prayther DC, Lee SA, Chi DS, et al. (2005)
Induction of p38- and gC1qR-dependent IL-8 expression in pulmonary
fibroblasts by soluble hepatitis C core protein. Respir Res 6: 105.
33. Eisen-Vandervelde AL, Yao ZQ, Hahn YS (2004) The molecular basis of HCV-
mediated immune dysregulation. Clin Immunol 111: 16–21.
34. Power C, McArthur JC, Nath A, Wehrly K, Mayne M, et al. (1998) Neuronal
death induced by brain-derived human immunodeficiency virus type 1 envelope
genes differs between demented and nondemented AIDS patients. J Virol 72:
9045–9053.
35. Vecil GG, Larsen PH, Corley SM, Herx LM, Besson A, et al. (2000) Interleukin-
1 is a key regulator of matrix metalloproteinase-9 expression in human neurons
in culture and following mouse brain trauma in vivo. J Neurosci Res 61:
212–224.
36. Johnston JB, Jiang Y, van Marle G, Mayne MB, Ni W, et al. (2000) Lentivirus
infection in the brain induces matrix metalloproteinase expression: role of
envelope diversity. J Virol 74: 7211–7220.
37. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005)
Production of infectious hepatitis C virus in tissue culture from a cloned viral
genome. Nat Med 11: 791–796.
38. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, et al. (1995) Distinct
HIV-1 env sequences are associated with neurotropism and neurovirulence.
Curr Top Microbiol Immunol 202: 89–104.
39. Yuki N, Matsumoto S, Tadokoro K, Mochizuki K, Kato M, et al. (2006)
Significance of liver negative-strand HCV RNA quantitation in chronic hepatitis
C. J Hepatol 44: 302–309.
40. Dickie P, Roberts A, Uwiera R, Witmer J, Sharma K, et al. (2004) Focal
glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to
HIV-associated nephropathy. Virology 322: 69–81.
41. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, et al. (2001) HIV-1
Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann
Neurol 49: 230–241.
42. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational
behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine
system. Brain Res 24: 485–493.
43. Ruggieri A, Franco M, Gatto I, Kumar A, Rapicetta M (2007) Modulation of
RANTES expression by HCV core protein in liver derived cell lines. BMC
Gastroenterol 7: 21.
44. Apolinario A, Majano PL, Lorente R, Nunez O, Clemente G, et al. (2005) Gene
expression profile of T-cell-specific chemokines in human hepatocyte-derived
cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus
proteins. J Viral Hepat 12: 27–37.
45. Martinez-Vicente M, Cuervo AM (2007) Autophagy and neurodegeneration:
when the cleaning crew goes on strike. Lancet Neurol 6: 352–361.
46. Orvedahl A, Levine B (2008) Autophagy and viral neurovirulence. Cell
Microbiol 10: 1747–1756.
47. Noorbakhsh F, Ramachandran R, Barsby N, Ellestad KK, Leblanc A, et al.
MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6
regulates astrocyte survival. Faseb J.
48. Zignego AL, Giannini C, Monti M, Gragnani L (2007) Hepatitis C virus
lymphotropism: lessons from a decade of studies. Dig Liver Dis 39(Suppl 1):
S38–45.
49. Sanchez MJ, Bergasa NV (2008) Hepatitis C associated cardiomyopathy:
potential pathogenic mechanisms and clinical implications. Med Sci Monit 14:
RA55–63.
50. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, et al. Hepatitis C virus
RNA localization in human carotid plaques. J Clin Virol 47: 72–75.
51. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell
culture-produced hepatitis C virus does not infect peripheral blood mononuclear
cells. Hepatology 48: 1843–1850.
52. Bode JG, Brenndorfer ED, Haussinger D (2008) Hepatitis C virus (HCV)
employs multiple strategies to subvert the host innate antiviral response. Biol
Chem 389: 1283–1298.
53. Moriishi K, Matsuura Y (2007) Host factors involved in the replication of
hepatitis C virus. Rev Med Virol 17: 343–354.
54. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, et al.
(2007) Cellular cofactors affecting hepatitis C virus infection and replication.
Proc Natl Acad Sci U S A 104: 12884–12889.
55. Moradpour D, Gosert R, Egger D, Penin F, Blum HE, et al. (2003) Membrane
association of hepatitis C virus nonstructural proteins and identification of the
membrane alteration that harbors the viral replication complex. Antiviral Res
60: 103–109.
56. Anthony IC, Arango JC, Stephens B, Simmonds P, Bell JE (2008) The effects of
illicit drugs on the HIV infected brain. Front Biosci 13: 1294–1307.
57. Yao ZQ, Nguyen DT, Hiotellis AI, Hahn YS (2001) Hepatitis C virus core
protein inhibits human T lymphocyte responses by a complement-dependent
regulatory pathway. J Immunol 167: 5264–5272.
58. Piller SC, Jans P, Gage PW, Jans DA (1998) Extracellular HIV-1 virus protein R
causes a large inward current and cell death in cultured hippocampal neurons:
implications for AIDS pathology. Proc Natl Acad Sci U S A 95: 4595–4600.
59. Refaeli Y, Levy DN, Weiner DB (1995) The glucocorticoid receptor type II
complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci U S A 92:
3621–3625.
60. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS (2000)
Interaction between complement receptor gC1qR and hepatitis C virus core
protein inhibits T-lymphocyte proliferation. J Clin Invest 106: 1239–1249.
61. Forton DM, Hamilton G, Allsop JM, Grover VP, Wesnes K, et al. (2008)
Cerebral immune activation in chronic hepatitis C infection: a magnetic
resonance spectroscopy study. J Hepatol 49: 316–322.
62. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P (2008) Depressive
symptoms in patients with chronic hepatitis C are correlated with elevated
plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett
430: 264–268.
63. Radkowski M, Bednarska A, Horban A, Stanczak J, Wilkinson J, et al. (2004)
Infection of primary human macrophages with hepatitis C virus in vitro:
induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol 85:
47–59.
64. Sanders VJ, Pittman CA, White MG, Wang G, Wiley CA, et al. (1998)
Chemokines and receptors in HIV encephalitis. Aids 12: 1021–1026.
65. Zheng JC, Huang Y, Tang K, Cui M, Niemann D, et al. (2008) HIV-1-infected
and/or immune-activated macrophages regulate astrocyte CXCL8 production
through IL-1beta and TNF-alpha: involvement of mitogen-activated protein
kinases and protein kinase R. J Neuroimmunol 200: 100–110.
66. Klein RS (2004) Regulation of neuroinflammation: the role of CXCL10 in
lymphocyte infiltration during autoimmune encephalomyelitis. J Cell Biochem
92: 213–222.
67. Mukaida N (2000) Interleukin-8: an expanding universe beyond neutrophil
chemotaxis and activation. Int J Hematol 72: 391–398.
HCV Core Neuropathogenesis
PLoS ONE | www.plosone.org 13 September 2010 | Volume 5 | Issue 9 | e1285668. Afkhami-Goli A, Liu SH, Zhu Y, Antony JM, Arab H, et al. (2009) Dual
lentivirus infection potentiates neuroinflammation and neurodegeneration: viral
copassage enhances neurovirulence. J Neurovirol 15: 139–152.
69. Pais TF, Figueiredo C, Peixoto R, Braz MH, Chatterjee S (2008) Necrotic
neurons enhance microglial neurotoxicity through induction of glutaminase by a
MyD88-dependent pathway. J Neuroinflammation 5: 43.
70. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, et al. (2003) Hepatitis C
virus core and nonstructural protein 3 proteins induce pro- and anti-
inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol
170: 5615–5624.
71. Barbasz A, Guevara-Lora I, Rapala-Kozik M, Kozik A (2008) Kininogen
binding to the surfaces of macrophages. Int Immunopharmacol 8: 211–216.
72. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, et al. (2005) TLR
signaling tailors innate immune responses in human microglia and astrocytes.
J Immunol 175: 4320–4330.
73. Fernando LP, Natesan S, Joseph K, Kaplan AP (2003) High molecular weight
kininogen and factor XII binding to endothelial cells and astrocytes. Thromb
Haemost 90: 787–795.
HCV Core Neuropathogenesis
PLoS ONE | www.plosone.org 14 September 2010 | Volume 5 | Issue 9 | e12856